Incidences and prognostic impact of c-KIT, WT1, CEBPA, and CBL mutations, and mutations associated with epigenetic modification in core binding factor acute myeloid leukemia: A multicenter study in a Korean population

Annals of Laboratory Medicine

Volumn 35, Issue 3, 2015, Pages 288-297

  Park, Sang Hyuk ^a   Lee, Hyun Ji ^b   Kim, In Suk ^c   Kang, Jeong Eun ^d   Lee, Eun Yup ^a   Kim, Hyeoung Joon ^e   Kim, Yeo Kyeoung ^e   Won, Jong Ho ^f   Bang, Soo Mee ^g   Kim, Hawk ^h   Song, Moo Kon ^a   Chung, Joo Seop ^a   Shin, Ho Jin ^a  

^a Pusan National University School of Medicine   (South Korea)

^b Korean Red Cross   (South Korea)

^c Pusan National University Yangsan Hospital   (South Korea)

^d Department of Laboratory Medicine Jinhae Yonsei Hospital   (South Korea)

^e Chonnam National University Research Institute of Medical Sciences   (South Korea)

^f Soonchunhyang University College of Medicine   (South Korea)

^g Seoul National University Bundang Hospital   (South Korea)

^h University of Ulsan College of Medicine   (South Korea)

Author keywords

Acute myeloid leukemia; C KIT; Core binding factor; Epigenetic modification; Incidence; Prognosis; WT1

Indexed keywords

CBL PROTEIN; CBL PROTEIN, HUMAN; CCAAT ENHANCER BINDING PROTEIN; CEBPA PROTEIN, HUMAN; CORE BINDING FACTOR; STEM CELL FACTOR RECEPTOR; WT1 PROTEIN; WT1 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; DISEASE FREE SURVIVAL; FEMALE; GENE TRANSLOCATION; GENETIC EPIGENESIS; GENETICS; HUMAN; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; SOUTH KOREA; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CCAAT-ENHANCER-BINDING PROTEINS; CHILD; CORE BINDING FACTORS; DISEASE-FREE SURVIVAL; EPIGENESIS, GENETIC; FEMALE; HUMANS; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-CBL; PROTO-ONCOGENE PROTEINS C-KIT; REPUBLIC OF KOREA; SURVIVAL RATE; TRANSLOCATION, GENETIC; WT1 PROTEINS; YOUNG ADULT;

EID: 84929627266     PISSN: 22343806     EISSN: 22343814     Source Type: Journal    
DOI: 10.3343/alm.2015.35.3.288     Document Type: Article

References (25)

1. Conway O'Brien E, Prideaux S, Chevassut T. The epigenetic landscape of acute myeloid leukemia. Adv Hematol 2014;2014:103175.
2. Murati A, Brecqueville M, Devillier R, Mozziconacci MJ, Gelsi-Boyer V, Birnbaum D. Myeloid malignancies: mutations, models and management. BMC Cancer 2012;12:304.
3. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999;93:3074-80.
4. Port M, Böttcher M, Thol F, Ganser A, Schlenk R, Wasem J, et al. Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 yr: a systematic review and meta-analysis. Ann Hematol 2014;93:1279-86.
5. Thol F, Damm F, Lüdeking A, Winschel C, Wagner K, Morgan M, et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol 2011;29:2889-96.
6. Yan XJ, Xu J, Gu ZH, Pan CM, Lu G, Shen Y, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 2011;43:309-15.
7. Fried I, Bodner C, Pichler MM, Lind K, Beham-Schmid C, Quehenberger F, et al. Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia. Haematologica 2012;97:246-50.
8. Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrózek K, Margeson D, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010;28:2348-55.
9. Wang X, Dai H, Wang Q, Wang Q, Xu Y, Wang Y, et al. EZH2 mutations are related to low blast percentage in bone marrow and -7/del(7q) in de novo acute myeloid leukemia. PLoS One 2013;8:e61341.
10. Naoe T and Kiyoi H. Gene mutations of acute myeloid leukemia in the genome era. Int J Hematol 2013;97:165-74.
11. Abdel-Wahab O, Pardanani A, Patel J, Wadleigh M, Lasho T, Heguy A, et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 2011;25:1200-2.
12. Rocquain J, Carbuccia N, Trouplin V, Raynaud S, Murati A, Nezri M, et al. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer 2010;10:401.
13. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994;84:3071-9.
14. Schmid D, Heinze G, Linnerth B, Tisljar K, Kusec R, Geissler K, et al. Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia. Leukemia 1997;11:639-43.
15. Bergmann L, Maurer U, Weidmann E. Wilms tumor gene expression in acute myeloid leukemias. Leuk Lymphoma 1997;25:435-43.
16. Miglino M, Colombo N, Pica G, Grasso R, Clavio M, Bergamaschi M, et al. WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia. Leuk Lymphoma 2011;52:1961-9.
17. Kim HJ, Ahn HK, Jung CW, Moon JH, Park CH, Lee KO, et al. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement. Ann Hematol 2013;92:163-71.
18. Park SH, Chi HS, Min SK, Park BG, Jang S, Park CJ. Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia. Leuk Res 2011;35:1376-83.
19. Boissel N, Leroy H, Brethon B, Philippe N, de Botton S, Auvrignon A, et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 2006;20:965-70.
20. Paschka P, Marcucci G, Ruppert AS, Mrózek K, Chen H, Kittles RA, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 2006;24:3904-11.
21. Allen C, Hills RK, Lamb K, Evans C, Tinsley S, Sellar R, et al. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. Leukemia 2013;27:1891-901.
22. Park SH, Min SK, Park BG, Jang S, Park CJ, Chi HS. Clinical usefulness of plasma specimens for detection of nucleophosmin 1 gene mutations in patients with normal karyotype acute myeloid leukemia. Leuk Res 2011;35:e159-60.
23. Park SH, Chi HS, Cho YU, Jang S, Park CJ. CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic risk. Leuk Res 2013;37:1488-94.
24. Verhaak RG, Goudswaard CS, van Putten W, Bijl MA, Sanders MA, Hugens W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005;106:3747-54.
25. Mrózek K, Marcucci G, Paschka P, Bloomfield CD. Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia. Curr Opin Oncol 2008;20:711-8.